The theranostic agent not only can effectively distinguish different EGFR-expressing pancreatic cancer cells, but also can evaluate non-invasive methods for different targeting effects by MRI. Combined antibodies and magnetic targeting, the theranostic agent can efficiently inhibit or kill AsPC-1 cells. Here, EGFR is linked to familial pancreatic carcinoma.